Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2212856Source: DataRank Database

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer is a research paper published in New England Journal of Medicine (2023). On theSindex it has a DataRank of 4.5. It has been cited 216 times, with 100 citing works in its 1-hop citation network.

N/A

4.5DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access216 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02308085

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (23 grants)Impact (FWCI 25.17)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 18%Citation Network 82%

Base Score Contribution

0.807

From this paper's citation signal

Citation Network Contribution

3.7

From 97 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer
JAMA Oncology20256 citations6 referencesContributes 0.324
Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE
Nature Reviews Clinical Oncology20238 citations10 referencesContributes 0.220
Cryopreservation of ovarian tissue for fertility preservation in breast cancer patients: time to stop?
Reproductive BioMedicine Online202411 citations15 referencesContributes 0.166
POSITIVE Results for Breast Cancer Survivors Who Desire Pregnancy
New England Journal of Medicine20236 citations12 referencesContributes 0.162
Pregnancy-Associated Breast Cancer: Key Concepts for Optimizing Diagnosis and Treatment
JCO Oncology Practice20246 citations13 referencesContributes 0.150

Authors (39)

Samuel M. Niman,Monica Ruggeri ORCID,Fedro A. Peccatori ORCID,Hatem A. Azim ORCID,Marco Colleoni ORCID

Live enrichment

PubMed:37133584 PMC:PMC10358451 OpenAlex:https://openalex.org/W4367833987

NCI NIH HHS

Grant: UG1 CA189974

NCI NIH HHS

Grant: UG1 CA233180

NCI NIH HHS

Grant: U10 CA180868

NCI NIH HHS

Grant: U10 CA180888

NCI NIH HHS

Grant: UG1 CA189867

NCI NIH HHS

Grant: UG1 CA233196

Health Research Board

Grant: CTIN-2021-001

NCI NIH HHS

Grant: U24 CA196171

Health Research Board

Grant: CTIC-2021-003

NCI NIH HHS

Grant: U10 CA180863

NCI NIH HHS

Grant: UG1 CA189828

NCI NIH HHS

Grant: UG1 CA189823

National Institutes of Health

Grant: 5U10CA180868-09

NRG Oncology Network Group Operations Center

National Institutes of Health

Grant: 5UG1CA189974-10

SWOG NCORP Research Base

National Institutes of Health

Grant: 5UG1CA189828-10

ECOG-ACRIN NCORP Research Base

National Institutes of Health

Grant: 3U10CA180888-03S1

SWOG Network Group Operations Center of the NCTN

National Institutes of Health

Grant: 5U10CA180863-08

Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

National Institutes of Health

Grant: 3UG1CA189867-03S1

NRG Oncology NCORP Research Base

National Institutes of Health

Grant: 5UG1CA233196-03

Johns Hopkins University NCTN Lead Academic Site Program

National Institutes of Health

Grant: 3U24CA196171-04S1

THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE

National Institutes of Health

Grant: 5UG1CA189823-04

Alliance NCORP Research Base

ETOP IBCSG Partners Foundation

Alliance for Clinical Trials in Oncology

FWCI

25.17

Citation Percentile

1.0%

Influential Citations

Citation Trend

2023

2024

2025

2026

greenLicense: http://www.nejmgroup.org/legal/terms-of-use.htm

repositoryhttps://hal.science/hal-05223723/document

GREENhttps://hal.science/hal-05223723/document

repositoryhttps://hal.science/hal-05223723/document

publisherhttp://www.nejm.org/doi/pdf/10.1056/NEJMoa2212856

repositoryhttps://hal.science/hal-05223723

Fields of Study

Cancer Risks and FactorsReproductive Biology and FertilityBreast Cancer Treatment StudiesMedicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyFemaleHumansNeoplasm Recurrence, LocalPregnancyProspective StudiesChemotherapy, AdjuvantDisease-Free SurvivalWithholding Treatment

Keywords

Endocrine systemMedicinePregnancyBreast cancerObstetricsCancerOncologyGynecologyInternal medicineHormoneBiologyAdultComplications of Pregnancy610Hematology/Oncology GeneralBreast NeoplasmsHematology/OncologyCombined Modality TherapyDisease-Free SurvivalWithholding Treatment[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieChemotherapy, AdjuvantAntineoplastic Combined Chemotherapy ProtocolsObstetrics/GynecologyHumansFemaleObstetrics/Gynecology GeneralProspective StudiesNeoplasm Recurrence, LocalPregnancy after Breast Cancer

Sustainable Development Goals

SDG 0: Good health and well-being